ArticleAmerican journal of cancer research2021
Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China.
Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Very early recurrence in pancreatic cancer: Redefining prognostic markers and surveillance strategies.World journal of gastrointestinal surgery · 2026Article
- Postoperative recurrence patterns and anatomy-stratified clinical target volume delineation in pancreatic cancer.Radiation oncology (London, England) · 2026Article
- Early postoperative recurrence prediction in pancreatic ductal adenocarcinoma: a nomogram based on dual-energy computed tomography andQuantitative imaging in medicine and surgery · 2026Article
- Very early recurrence after pancreatic cancer resection: Unmasking the "biological R2" enigma and rethinking prognostic paradigms.World journal of gastrointestinal surgery · 2025Article
- A CT-Based Deep Learning Radiomics Nomogram for Early Recurrence Prediction in Pancreatic Cancer: A Multicenter Study.Annals of surgical oncology · 2025Article
- Development and Validation of a Predictive Model for Occult Liver Metastasis in Pancreatic Ductal Adenocarcinoma Using Subjective Imaging and Clinical Data.Cancer medicine · 2025Article
- Nomogram based on preoperative contrast-enhanced CT predicts early liver metastasis in pancreatic ductal adenocarcinoma.Quantitative imaging in medicine and surgery · 2025Article
- Preoperative computed tomography-based risk stratification model validation for postoperative pancreatic ductal adenocarcinoma recurrence.World journal of gastrointestinal surgery · 2025Article
- Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single-center retrospective study in China.Journal of applied clinical medical physics · 2025Article
- Article
- Postoperative serum tumor markers-based nomogram predicting early recurrence for patients undergoing radical resections of pancreatic ductal adenocarcinoma.World journal of gastrointestinal surgery · 2024Article
- Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.Annals of surgical oncology · 2024Article
- Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis.Frontiers in oncology · 2024Article
- The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer.BMC cancer · 2023Article
- The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?Hepatobiliary surgery and nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A precise classification of early recurrence (ER) after radical surgery of pancreatic ductal adenocarcinoma (PDAC) has not been standardized. We aim to develop an optimal cut-off based on scientific evidence to distinguish early and late recurrence (LR) for PDAC after radical surgery and develop a predictive model for ER of PDAC. The best threshold for recurrence-free survival (RFS) was assessed with a minimum
Indexed as
Identifiers
34249444PMC8263647W3180787376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.